Monthly Archives: July 2017


Clinical trial for stem-cell therapy to reverse liver cirrhosis – The Straits Times

SINGAPORE - The use of stem cells to reverse liver cirrhosis - or the hardening of the liver - is being explored in a clinical trial.

Conducted by a multi-centre team led by the National University Hospital (NUH), doctors aim to determine if stem cell therapy can improve liver function.

Previously, liver cirrhosis, caused by various diseases such as chronic hepatitis B and non-alcoholic fatty liver disease, was thought to be irreversible.

A liver transplant provides a definitive cure to end-stage cirrhosis.

However, in Singapore, less than 5 per cent of end-stage liver cirrhosis patients receive a liver transplant.

The number of people on the waiting list for a liver transplant has been increasing over the years, according to statistics from the Ministry of Health.

In 2007, there were nine on the waiting list, compared with 57 last year. There are around 50 waiting for a liver transplant this year.

Also, many patients do not fulfil the eligibility criteria to receive a liver transplant due to other health complications or being above the age limit of 70 years.

The $2.6 million study, which was launched on Tuesday (July 11),is funded by the National Medical Research Counciland 46 patients will be recruited for it. It will run for four years and patients will not need to bear the costs of the stem cell treatment.

Stem cells will be taken from a patient's own bone marrow and will be isolated and injected directly into the patient's liver to initiate the repair.

Similar therapy treatments have been conducted overseas in countries such asEgypt and India, although they have not been fully evaluated for efficacy.

Associate Professor Dan Yock Young, a senior consultant in the division of gastroenterology and hepatology at NUH, said: "We are conducting the study in a systematic and scientific mannerto get definitive evidence of the effects of the treatment."

He also notes that the stem cell therapy is not a substitute for a liver transplant. "This treatment is not intended to pull patients off the waiting list, but provide an option for those who are not eligible for a transplant."

Original post:
Clinical trial for stem-cell therapy to reverse liver cirrhosis - The Straits Times

CReM Stem Cell Researcher Is Innovator of the Year – BU Today

Those who know ancient historythe first decade of the 21st centuryrecall that embryonic stem cell research was a combustible issue, with supporters cheering the potential to create new tissues from stem cells and opponents decrying the destruction of human embryos that it required. A breakthrough arrived in 2006, when a Japanese researcher developed induced pluripotent stem cells (iPS), adult cells that behaved like embryonic stem cells and had an amazing ability to develop into muscles, skin, nerves, and almost any other cell type. Two years later, a second breakthrough, this one by Gustavo Mostoslavsky, a School of Medicine associate professor of gastroenterology, produced a tool that made it simpler and more efficient to generate iPS. BU patented his tool, called STEMCCA, and he says that its been adopted by more than 700 laboratories worldwide for making iPS.

That contribution to the field has earned Mostoslavsky this years University Innovator of the Year award. The Technology Developmentoffice presents the award to a faculty member whose research yields inventions or innovations benefiting society. Mostoslavsky will receive the award today at BUs annual Tech, Drugs, and Rock n Roll networking event connecting BU researchers and Boston entrepreneurs.

I was humbly surprised and happy, he says, when Gloria Waters, vice president and associate provost for research, emailed him the news. Sometimes it is easy to lose perspective when we get busy on the many tasks of running a labgrant writing, mentoring, budget, and so forthso I guess it is nice, once in a while, to just stop and enjoy the moment, enjoy what we have done so far, and even better, if on the way we have helped many others succeed.

One way Mostoslavsky has helped others succeedthe way that makes him most proud, he saysis to have cofounded, in 2010, BUs Center for Regenerative Medicine, which he codirects. The center, which pursues stem cell research with an emphasis on lung, blood, and gastrointestinal tract diseases, practices open source biology: sharing its discoveries with scientists around the world for free rather than patenting them. In 2013, CReM moved into its own physical quarters on Albany Street on the Medical Campus.

I am delighted to see Dr. Mostoslavskys colleagues choose him for this award, says Waters. STEMCCA has dramatically improved the efficiency with which new stem cells can be generated to treat disease. His success in patenting a tool that has become industry-standard, at the same time as he and the codirectors of the CReM have become renowned for their open source biology, serves as a model to students and other researchers of how to advance science through sharing, at the same time protecting important intellectual property.

More:
CReM Stem Cell Researcher Is Innovator of the Year - BU Today

New approach may kill tumor cells in the brain – Harvard Gazette

Investigators from Brigham and Womens Hospital (BWH) and the Harvard Stem Cell Institute (HSCI) may have discovered a way to kill tumor cells that have metastasized to the brain.

The team has developed cancer-killing viruses that can deliver stem cells via the carotid artery, and applied them to metastatic tumors in the brains of clinically relevant mouse models. The elimination of metastatic skin cancer cells from the brains of these preclinical models resulted in prolonged survival, the investigators report. The study, published online this week in the journal PNAS, also describes a strategy of combining this therapy with immune checkpoint inhibitors.

Metastatic brain tumors often from lung, breast, or skin cancers are the most commonly observed tumors within the brain and account for about 40 percent of advanced melanoma metastases. Current therapeutic options for such patients are limited, particularly when there are many metastases, said Khalid Shah, director of the Center for Stem Cell Therapeutics and Imaging (CSTI) in the BWH Department of Neurosurgery, who led the study. Our results are the first to provide insight into ways of targeting multiple brain metastatic deposits with stem-cell-loaded oncolytic viruses that specifically kill dividing tumor cells.

In their search for novel, tumor-specific therapies that could target multiple metastases in the brain without damaging adjacent tissues, the research team first developed different BRAF wild-type and mutant mouse models that more closely mimicked what is seen in patients.

They found that injecting patient-derived, brain-seeking melanoma cells into the carotid arteries of the preclinical models resulted in metastatic tumors forming throughout the brain, mimicking what is seen in advanced melanoma cancer patients. The injected cells express markers that allow them to enter the brain and are labeled with bioluminescent and fluorescent markers to enable tracking by imaging technologies.

To devise a potential new therapy, the investigators engineered a population of bone marrow-derived mesenchymal stem cells loaded with oncolytic herpes simplex virus (oHSV), which specifically kills dividing cancer cells while sparing normal cells.

Previous research by Shah and his colleagues had shown that different stem cell types were naturally attracted to tumors in the brain. After first verifying that stem cells injected to the brain would travel to multiple metastatic sites and not to tumor-free areas in their model, the team injected the oHSV-laden stem cells into the carotid arteries of metastasis-bearing mice. This led to significantly slower tumor growth and increased survival, compared with the models that received unaltered stem cells or control injections.

Shah and his colleagues also developed an immunocompetent melanoma mouse model and explored treatments with both stem cell-loaded oHSV and immune checkpoint blockers such as those that target the PD-1/PD-L1 pathway. They found that PD-L1 immune checkpoint blockade significantly improved the therapeutic efficacy of stem cell-based oncolytic virotherapy in melanoma brain metastasis.

We are currently developing similar animal models of brain metastasis from other cancer types, as well as new oncolytic viruses that have the ability to specifically kill a wide variety of resistant tumor cells, said Shah, who is also a professor at Harvard Medical School and a principal faculty member at the Harvard Stem Cell Institute. We are hopeful that our findings will overcome problems associated with current clinical procedures. This work will have direct implications for designing clinical trials using oncolytic viruses for metastatic tumors in the brain.

The study was supported by a Department of Defense Idea Award and a grant from the National Institutes of Health.

Read more:
New approach may kill tumor cells in the brain - Harvard Gazette

Cesca Therapeutics subsidiary acquires assets of Sacramento’s SynGen Inc. – Sacramento Bee


Sacramento Business Journal
Cesca Therapeutics subsidiary acquires assets of Sacramento's SynGen Inc.
Sacramento Bee
Rancho Cordova's Cesca Therapeutics Inc., a stem cell medicine and medical technology company, announced Monday that its subsidiary has acquired the assets of SynGen Inc., the privately held Sacramento medical device company specializing in cell ...
Cesca Therapeutics Acquires the Cell Processing Systems of SynGen Under Asset Acquisition AgreementNasdaq
Cesca Therapeutics Inc (KOOL)'s Stock Is Buy After Today's Huge IncreaseFinance News Daily

all 16 news articles »

See the article here:
Cesca Therapeutics subsidiary acquires assets of Sacramento's SynGen Inc. - Sacramento Bee

Stem Cell Treatments in Use at Clinics Worldwide Need Regulation … – Multiple Sclerosis News Today

Advertising forstem cell therapies not supported by clinical researchoftenmadedirectly to patients and sometimes promoted as a cure for diseases like multiple sclerosis or Parkinsons is a growing problem that needs to be addressed and regulated, a team of leading experts say, calling suchstem cell tourism potentially unsafe.

Stem cell tourism is the unflattering name given to the practice of encouragingpatients totravel outside their home country to undergo suchtreatment, typicaly at a private clinic.

The article, titledMarketing of unproven stem cellbased interventions: A call to actionandrecently published inthe journal Science Translational Medicine, was co-authored by scientistswith universities and hospitals in the U.S., Canada, U.K., Belgium, Italy, Japan, and Australia. It focuses on the global problem of thecommercial promotion of stem cell therapies and ongoing resistance to regulatory efforts.

Its authors suggest that a coordinated approach, at national and international levels, be focused on engagement, harmonization, and enforcement in order to reduce risks associated with direct-to-consumer marketing of unproven stem cell treatments.

Treatments involving stem cell transplants are now being offered by hundreds of medical institutions worldwide, claiming efficacy in repairing tissue damaged by degenerative disorders like MS, even thoughthose claim often lack or are supported bylittle evidence .

They alsonoted that the continued availability of these treatments undermines the development of rigorously tested therapies, and potentially canendanger a patients life.

The researchers emphasizethat tighter regulations on stem cell therapy advertising are needed, especiallyregarding potential clinical benefits. They support the establishment ofinternational regulatory standards for the manufacture and testing of human cell and tissue-based therapies.

Many patients feel that potential cures are being held back by red tape and lengthy approval processes. Although this can be frustrating, these procedures are there to protect patients from undergoing needless treatments that could put their lives at risk, Sarah Chan, a University of Edinburgh Chancellors Fellow and report co-author, saidin anews release.

Chan and her colleagues are also calling for the World Health Organization to offer guidance on responsible clinical use of cells and tissues, as it does for medicines and medical devices.

Stem cell therapies hold a lot of promise, Chan said, but we need rigorous clinical trials and regulatory processes to determine whether a proposed treatment is safe, effective and better than existing treatments.

According to the release, the report and its recommendationsfollowed the death of two children at a German clinic in 2010. The clinichas since been shut down.

Certainstem cell therapies mostly involving blood and skin stem cells have undergone rigorous testing in clinical trials, the researchers noted. A number of theseresulted in aprovedtreatments for certain blood cancers, and to grow skin grafts for patients with severe burns.

Information about the current status of stem cell research andpotential uses of stem cell therapiesis availableon the websiteEuroStemCell.

View original post here:
Stem Cell Treatments in Use at Clinics Worldwide Need Regulation ... - Multiple Sclerosis News Today

A tall order: Giraffe receives stem-cell therapy for chronic arthritis – Source

How do veterinarians help a giraffe ease its arthritis pain? Well, it takes a little more than an aspirin and a gulp of water.

Recently, Colorado State University veterinarians traveled to Cheyenne Mountain Zoo to help Mahali, a 14-year-old giraffe, with arthritis pain in his front left hoof.

Arthritis is a common problem for giraffes, especially geriatric giraffes like Mahali. Who can blame them? Weighing in at 2,000 pounds on average, their four feet support more than one ton of weight. Thats like carrying two grand pianos on your back all day.

With its 17-giraffe herd trained for voluntary husbandry, including hoof trims, blood draws and radiographs, Cheyenne Mountain Zoo is uniquely suited to help find better arthritis treatments for giraffes.

Dr. Amanda Morphet, who is training to specialize in exotic and zoo animal medicine at CSU, believes stem-cell therapy can help alleviate arthritis pain.

Currently, arthritis in these megavertebrates is managed through corrective hoof trims, non-steroidal anti-inflammatories, cold-laser therapy and pain medications. But, these practices are not always enough to keep giraffes, which can live up to 30 years, comfortable as they age.

CSU veterinarians Dr. Val Johnson and Dr. Amanda Morphet, and the zoos lead veterinarian Dr. Liza Dadone, are determined to discover a more successful way to treat these gentle giants, and they believe stem-cell therapy is the answer.

Stem-cell therapy has resulted in dramatic clinical improvement in some cases of arthritis in horses and other species, but has not, until now, been attempted in giraffes, Johnson said.

The university and the zoo began working together seven years ago, when CSU veterinarian Dr. Matt Johnston and zoo veterinarians initiated a partnership to treat zoo animals while teaching veterinary students.

This specific stem-cell research partnership began in 2016, when Johnson and Dadone started treating a geriatric elephant for arthritis with stem-cell therapy.

Johnson, who is researching regenerative medicine at CSU, has safely treated a mountain lion, tiger, wolf, coyote and dogs with stem cells over the past five years.

Regenerative medicine is a promising new avenue for treatment of chronic age-related degenerative diseases, Johnson said. I want to develop more effective methods for treating animals.

Johnson and Dadone ran a crowdfunding campaign to develop a technique to grow stem cells from giraffe blood and grow multiple treatments of stem cells. The online campaign was quickly funded.

Cheyenne Mountain Zoo staff and veterinarians use hoof-trimming techniques on giraffes to maintain foot health and help prevent foot arthritis in older giraffes. (Photo by Andrew Schroeder)

In April, Morphet and Johnson traveled with two CSU anesthesiologists, Dr. Marlis Rezende and Dr. Khursheed Mama, to Colorado Springs for the procedure on Mahali.

Mahali was in pain. He wouldnt leave pressure on his front left foot for longer than a minute or two, said Morphet, who is training to specialize in exotic and zoo animal medicine at CSUs James L. Voss Veterinary Teaching Hospital.

Mahali is trained for general footwork, but injecting stem cells requires absolute stillness. Anesthetizing a giraffe, however, is especially dangerous for the animal.

With the length of the neck and limbs, falling during induction and recovery is a big concern, Dr. Morphet said.

The large procedure room was packed tight with veterinarians, zoo staff and volunteers who assisted Mahali, which included repositioning his body, and elevating his head at different angles every 10 minutes to prevent muscle spasms, aspiration and brain swelling. The team of volunteers scooped sand under his back to help Mahali roll up once he awoke.

If this sounds like intense physical work, it is.

Veterinarians took radiographs and successfully injected stem cells while Mahali was anesthetized. Meanwhile, a farrier team trimmed his hooves.

The stem cells, which were grown from giraffe blood, were injected through a vein near Mahalis inflamed hoof. The cells remained at the injection site for 20 minutes to improve absorption into the hoof.

Under the watchful care of veterinarians and zoo staff, Mahali came out of anesthesia safely. And then, they waited six long weeks for the stem cells to take effect.

This was the first time a giraffe has received stem-cell therapy to treat arthritis. The big question: Did it work?

Six weeks after the procedure, Morphet and veterinary students visited Mahali for a check-up.

Weve seen a dramatic improvement in his clinical signs, Morphet said. Not only to his comfort level but the quality of his hoof. Hes letting us work with his feet.

Dadone, the zoo veterinarian, used a thermal camera to view the heat distribution in Mahalis feet.

With the thermal imaging, you can see hot spots in the limbs, said Kara Gendron, a fourth-year veterinary student. The warmer it is, the more likely its inflamed and painful. His left hoof was still a little warmer, but compared to what we were seeing initially, it was very similar to his right [hoof]. So, hes actually doing a lot better.

See the rest here:
A tall order: Giraffe receives stem-cell therapy for chronic arthritis - Source

Human Neural Stem Cell Therapy for Chronic Ischemic Stroke | GEN – Genetic Engineering & Biotechnology News

Stem cells and stroke

The past decade has seena rise in the number of stem cell-derived therapies targeting ischemic stroke in preclinical and early clinical studies. Corroborated by numerous scientific reports, the therapeutic benefits of stem cells include an extension of the time window for drug intervention, improvement of neurological deficits, reduction of infarct volume, pro-regenerative cerebral reorganization, mitigation of poststroke neuro-inflammation, and tissue restoration, all of which depend on the time after infarct, cell type used, and route of administration13. The wide range of effects observed for stem cell therapies demonstrates that functional recovery after stroke occurs via multiple mechanisms rather than a single target46. Research indicates that the mode of action may depend on the stem cell type and other key factors, including infarct size and location, mode of intervention, and timing poststroke68. Thus, some understanding of the cellular, molecular, and biochemical events that are involved in the mode of action of a stem cell type is a prerequisite to improving and optimizing its therapeutic benefits.

Our 2012 review of cell therapy in stroke showed the wide variety of cell types used preclinically and clinically in stroke treatment research1. Mesenchymal stromal cells (MSCs) of multiple origins and phenotypes are most commonly employed in the literature and mainly applied systemically in high doses in acute stroke settings, because of their nonengraftment and potent drug-like biological activity. Neural stem cells (NSCs), by contrast, are multipotent cells that are derived from developing or adult brain tissue or differentiated from pluripotent cells such as embryonic stem cells (ESCs) or induced pluripotent stem cells (iPSCs) in culture. These stem cells have both capacity for engraftment and neural cell differentiation as well as potent biological activity and are delivered intracerebrally in smaller volumes and cell doses; we believe that they are more suitable in patients presenting with pre-existing chronic, stable disability. Currently, there is a growing number of hNSC-derived therapies in preclinical development for ischemic stroke (Table). Leading these therapies, ReNeuron's CTX0E03 cell line (CTX) has been evaluated in a first-in-human, single-center trial in patients with moderate-to-severe disability, 6 months to 5 years after ischemic stroke9. Currently, a Phase II stroke trial in patients with upper-limb disability, 312 months poststroke is underway across multiple sites in the United Kingdom (clinicaltrials.govNCT02117635). In this review, we summarize nearly 15 years of research behind the CTX line and discuss its mode of action together with implications for therapeutic potential in stroke disability.

Link:
Human Neural Stem Cell Therapy for Chronic Ischemic Stroke | GEN - Genetic Engineering & Biotechnology News

Stem cell-based therapy for targeting skin-to-brain cancer – Medical Xpress

July 10, 2017 Credit: CC0 Public Domain

Investigators from Brigham and Women's Hospital (BWH) and the Harvard Stem Cell Institute have a potential solution for how to kill tumor cells that have metastasized to the brain. The team has developed cancer-killing viruses that can deliver stem cells via the carotid artery, and applied them to metastatic tumors in the brain of clinically relevant mouse models. The investigators report the elimination of metastatic skin cancer cells from the brain of these preclinical models, resulting in prolonged survival. The study, published online this week in the journal PNAS, also describes a strategy of combining this therapy with immune check point inhibitors.

"Metastatic brain tumors - often from lung, breast or skin cancers - are the most commonly observed tumors within the brain and account for about 40 percent of advanced melanoma metastases. Current therapeutic options for such patients are limited, particularly when there are many metastases," says Khalid Shah, MS, PhD, director of the Center for Stem Cell Therapeutics and Imaging (CSTI) in the BWH Department of Neurosurgery, who led the study. "Our results are the first to provide insight into ways of targeting multiple brain metastatic deposits with stem-cell-loaded oncolytic viruses that specifically kill dividing tumor cells."

In their search for novel, tumor-specific therapies that could target multiple brain metastases without damaging adjacent tissues, the research team first developed different BRAF wild type and mutant mouse models that more closely mimic what is seen in patients. They found that injecting patient-derived, brain-seeking melanoma cells into the carotid artery of these preclinical models resulted in the formation of many metastatic tumors throughout the brain, mimicking what is seen in advanced melanoma cancer patients. The injected cells express markers that allow them to enter the brain and are labelled with bioluminescent and fluorescent markers to enable tracking by imaging technologies.

To devise a potential new therapy, the investigators engineered a population of bone marrow derived mesenchymal stem cells loaded with oncolytic herpes simplex virus (oHSV), which specifically kills dividing cancer cells while sparing normal cells. Previous research by Shah and his colleagues shows that different stem cell types are naturally attracted toward tumors in the brain. After first verifying that stem cells injected to the brain would travel to multiple metastatic sites and not to tumor-free areas in their model, the team injected stem cells loaded with oHSV into the carotid artery of metastasis-bearing mice.. Injecting the stem cells loaded with oHSV into the carotid artery, a likely strategy for clinical application, led to significantly slower tumor growth and increased survival, compared with the models that received unaltered stem cells or control injections. The oHSV loaded stem cells are ultimately killed by oHSV mediated oncolysis, preventing the engineered cells from persisting within the brain, which is an important safety component in the therapeutic use of these stem cells.

Due to an increasing body of evidence which suggests that the host immune response may be critical to the efficacy of oncolytic virotherapy, Shah and his colleagues also developed an immunocompetent melanoma mouse model and explored treating with both stem cell loaded oHSV and immune checkpoint blockers such as the ones that target the PD-1/PD-L1 pathway. They found that PD-L1 immune checkpoint blockade significantly improved the therapeutic efficacy of stem cell based oncolytic virotherapy in melanoma brain metastasis.

"We are currently developing similar animal models of brain metastasis from other cancer types as well as new oncolytic viruses that have the ability to specifically kill a wide variety of resistant tumor cells," said Shah, who is also a professor at Harvard Medical School and a principal faculty member at the Harvard Stem Cell Institute. "We are hopeful that our findings will overcome problems associated with current clinical procedures. This work will have direct implications for designing clinical trials using oncolytic viruses for metastatic tumors in the brain."

Explore further: Stem-cell-based therapy promising for treatment of breast cancer metastases in the brain

More information: Wanlu Du el al., "In vivo imaging of the fate and therapeutic efficacy of stem cell-loaded oncolytic herpes simplex virus in advanced melanoma," PNAS (2017). http://www.pnas.org/cgi/doi/10.1073/pnas.1700363114

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

View original post here:
Stem cell-based therapy for targeting skin-to-brain cancer - Medical Xpress

‘That’s the story of the American Dream, right?’ – Post-Bulletin

As a poor youngster staring at a dead-end future in Mexico, Alfredo Quinones-Hinojosa would often lay on the roof of his ramshackle home to dream of a brighter future.

Not even he dared dream his life would become this compelling.

Affectionately known as "Dr. Q," Quinones-Hinojosa recently was hired to be Mayo Clinic's chairman of neurologic surgery at its expanding Florida campus while leading federal research to cure brain cancer.

And, after long consideration, he's also given Disney the green light to turn his life story into a movie.

Expectations are high for the dramatic version of Dr. Q's life, especially since Brad Pitt's Plan B Entertainment's credits includes "12 Years A Slave," "Moonlight," "Selma" and "The Departed," among other blockbusters. The script is expected to be completed by the end of 2017 and it may hit theaters by the end of 2018.

'Knew something good would happen'

While it won't be a true documentary, the truth appears to need little embellishment.

"I used to go to the roof of my house and look at the stars I knew something good was going to happen," Dr. Q said last week by phone from Florida. "There's a lot of people who immigrate to the U.S., but there's not very many who came from nothing to be where (I am) today. That's the story of the American dream, right?"

It's a timely topic with unambiguous political overtones. The Trump administration has cracked down on immigration and increased deportation efforts, which has raised the profile of sanctuary cities across the country.

Dr. Q entered this country illegally, and while he is now a U.S. citizen, it's an open question whether he would have been allowed to reach his current heights in today's politicized climate. As an 18-year-old who jumped a border fence to enter the United States in 1988, he didn't speak English, had no immigration paperwork and was essentially broke.

His first few years were spent in the fields as a migrant worker, earning enough money to learn English at a California community college. He overcame those obstacles to earn an academic scholarship at UC-Berkeley in 1991.

Three years later, his unusual ascent saw him enroll at Harvard, paving the way for him to become a brain surgeon.

'Real people who are changing the world'

The rags-to-riches immigrant story first caught the attention of Plan B's studio execs way back in 2007, while Dr. Q was Professor of Neurosurgery and Oncology, Neurology, and Cellular and Molecular Medicine and Director of the Brain Tumor Stem Cell Laboratory at Johns Hopkins. Jeremy Kleiner, who is now Plan B's co-president with Pitt, made his initial pitch to Dr. Q in 2007.

Dr. Q spent the next eight years respectfully declining Kleiner's periodic overtures. He finally reconsidered after seeing "12 Years A Slave," which won best picture at the 2015 Oscars.

"The world has a tremendous appetite for real stories," Dr. Q said. "I always tell people, 'I'm not an expert on immigration, I'm an expert on brain cancer and brain surgery.' Why my story resonates is we need stories of real people who are changing the world.

"I'm not a fancy person. I still take the trash out of my house and my kids always make fun of me because I know a lot about very little. At the end of the day, I'm just a regular guy but my patients may think differently. They put their lives in my hands."

While filmmakers have been chasing Dr. Q's story for about a decade, Mayo Clinic's pursuit is actually longer. He turned down a 2005 job offer at Mayo's Rochester campus to work at Johns Hopkins.

Dr. Q's decision this April to join the Mayo system finally! was hailed as "a coup" by Gianrico Farrugia, CEO of Mayo's Jacksonville campus. His arrival coincides with a $100 million expansion project, aimed at making Jacksonville a destination medical center for that part of the country and Latin America.

Construction is expected to start later this year on buildings to improve services for complex cancer patients and those seeking neurologic or neurosurgical care. That all falls under Dr. Q's purview.

"Any place in the world would be pleased to have him coming," Farrugia told the Florida-Times Union. "It's a real coup to have him coming to Florida. I think he will have a remarkable impact on Jacksonville."

Forbes has named Dr. Q one of the most creative Mexicans in the world, while Popular Science has also dubbed him among the "Brilliant Ten" for his cancer research. The prestigious William J. and Charles H. Mayo Professor also presented May 18 at Tedx Zumbro River at Autumn Ridge Church in Rochester about his quest to use stem cells to fight brain cancer.

While collaborating daily on an upcoming Disney movie that figures to make him a household name, Dr. Q's says he feels a particular kinship with Mayo due to its humble origins.

"They (Mayo Clinic's founders) went out in the middle of cornfields and built something that is unimaginable," Dr. Q said. "I came and basically went to work in the fields in California. I picked corn when I first came in 1987. I relate so much and in so many ways that I feel I have so many things in common with this amazing institution."

Read more:
'That's the story of the American Dream, right?' - Post-Bulletin

Renowned Cardiothoracic Surgeon, Zain Khalpey, MD, PhD, FETCS, FACS will be Honorably Mentioned in The … – PR NewsChannel (press release)

The International Association of HealthCare Professionals is pleased to welcome Zain Khalpey, MD, PhD, FETCS, FACS, a prominent Cardiothoracic Surgeon to their prestigious organization with his upcoming publication in The Leading Physicians of the World. Dr. Khalpey is a highly trained and qualified surgeon with a vast expertise in all facets of his work and an international reputation for his work with Artificial Hearts remodeling scars in hearts with laser therapy, stem cells and liquid matrices to build a program for heart recovery and regenerative medicine, using precision medicine, but more specifically metabolomics with new artificial intelligence platforms in cardiac surgery to change outcomes for the better. Dr. Khalpey is currently serving as an Associate Professor of surgery, medical imaging, physiological sciences, biomedical engineering, cell & molecular medicine, regenerative & translational medicine, and pharmacology at the University of Arizona College of Medicine in Tucson, Arizona. He also serves as Co-Director of the Heart Transplant and Perfusion Science Programs, Director of the Mechanical Circulatory Support and Artificial Heart Programs, and Director of Robotic Mitral Valve Program in the Division of Cardiothoracic Surgery at Banner University Medical Center. Furthermore, Dr. Khalpey is an Adjunct Professor at Columbia University.

Dr. Khalpey was educated at the University of London, where he graduated Summa Cum Laude with his Medical Degree in 1998. He then gained his PhD in cardiothoracic surgery, bioenergetics, and cardiac transplantation from Imperial College London. Dr. Khalpey completed extensive postgraduate training in both the United Kingdom and the United States. In the United Kingdom, Dr. Khalpey was awarded a very prestigious Winston Churchill Medal for his research as well as a highly prestigious lifetime Hunterian Professorship from the Royal College of Surgeons of England, where he remains a member. His research training to end his PhD was completed at the Mayo Clinic in Rochester, and Massachusetts General Hospital at Harvard in Boston. He then went on to finish his clinical general surgery residency and cardiothoracic heart surgery fellowship at the Brigham and Womens Hospital, also at Harvard in Boston. He went on to New York where he completed a Super-Fellowship in Heart Transplants and Mechanical Circulatory Support Therapies for Advanced Heart Failure, at New York Presbyterian Hospital at Columbia University. He is certified by the American Board of Thoracic Surgery, and has earned the coveted title of Fellow of the European Board of Thoracic and Cardiovascular Surgery and Fellow of the American College of Surgeons.

Dr. Khalpey is a distinguished member of the American Association for Thoracic Surgery, the Society of Thoracic Surgeons, the American Academy of Regenerative Medicine and the Board of Regenerative Medicine. For his extensive expertise and important work, he has been awarded the prestigious Fulbright Distinguished Chair in Medical Sciences in Europe Award. Awards in the Fulbright Distinguished Chairs Program in Europe are viewed as among the most prestigious accolades in the Fulbright Scholar Program. Dr Khalpey holds the coveted Endowed Tony S. Marnell Sr. Chair in Cardiovascular Research at the University of Arizona for his metabolic and stem cell research within the surgical tissue and stem cell biobank he created. Furthermore, Dr. Khalpey is the surgical director of the Extracorporeal Membrane Oxygenator Program, which is the only mobile ECMO service in the state of Arizona. Alongside his exceptional operative team of perfusionists and clinical fellows, Dr. Khalpey helped save NHL hockey player, Tucson Roadrunners Captain, Craig Cunninghams life after sudden cardiac arrest. Dr. Khalpey is the only person on the west coast who is routinely placing left ventricular assist devices (LVADS) through minimally invasive incisions, without the use of a bypass machine, and also strives to revolutionize organ transplantation. Dr. Khalpeys passion for what he does is unparalleled. He is renowned for his innovative and groundbreaking work, and has dedicated his life to providing the best solutions for his patients and community.

View Dr. Zain Khalpeys Profile Here:

https://www.findatopdoc.com/doctor/8137416-Zain-Khalpey-Cardiac-Surgeon-85755

Learn more about Dr. Khalpey here:

https://profiles.arizona.edu/person/zkhalpey and be sure to read his upcoming publication in The Leading Physicians of the World.

About FindaTopDoc.com

FindaTopDoc.com is a hub for all things medicine, featuring detailed descriptions of medical professionals across all areas of expertise, and information on thousands of healthcare topics. Each month, millions of patients use FindaTopDoc to find a doctor nearby and instantly book an appointment online or create a review. FindaTopDoc.com features each doctors full professional biography highlighting their achievements, experience, patient reviews and areas of expertise. A leading provider of valuable health information that helps empower patient and doctor alike, FindaTopDoc enables readers to live a happier and healthier life. For more information about FindaTopDoc, visit: http://www.findatopdoc.com

Go here to see the original:
Renowned Cardiothoracic Surgeon, Zain Khalpey, MD, PhD, FETCS, FACS will be Honorably Mentioned in The ... - PR NewsChannel (press release)